Who are TNF Inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira, Abrilada, Switch to a second anti-TNF drug alone, TDM-based infliximab intravenous therapy, Infliximab Adalimumab y Golimumab, Adalimumab with methotrexate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tnf-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

TNF Inhibitor — Competitive Intelligence Brief

TNF Inhibitor (tnf-inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal Antibody. Area: Immunology.

marketed Monoclonal Antibody TNF-alpha Immunology Small molecule Live · refreshed every 30 min

Target snapshot

TNF Inhibitor (tnf-inhibitor) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TNF Inhibitor TARGET	tnf-inhibitor	Pfizer	marketed	Monoclonal Antibody	TNF-alpha
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Switch to a second anti-TNF drug alone	Switch to a second anti-TNF drug alone	Védrines, Philippe, M.D.	marketed	TNF inhibitor (class-level; specific agent varies)	TNF-alpha
TDM-based infliximab intravenous therapy	TDM-based infliximab intravenous therapy	Asan Medical Center	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
Infliximab Adalimumab y Golimumab	Infliximab Adalimumab y Golimumab	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal Antibody class)

Pfizer · 3 drugs in this class
National Medical Research Center for Children's Health, Russian Federation · 1 drug in this class
Pfizer Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TNF Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/tnf-inhibitor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab